Regulatory & market landscape
Few investigational drugs are watched as closely as CagriSema, because it sits at the center of a multi-billion-dollar…
A drug the market is watching, not yet selling
Few investigational drugs are watched as closely as CagriSema, because it sits at the center of a multi-billion-dollar obesity market. Yet the sponsor states plainly that it is not approved in the US or EU: a US New Drug Application went in on 18 December 2025 and is still under review, and the FDA says plainly that it cannot be used in compounding under federal law.
This unit maps the regulatory reality, the market stakes that made a topline number move a stock price, and the athlete and legal considerations that follow from an unapproved metabolic drug.
Key terms
The regulatory status
The headline is simple: the sponsor states that CagriSema is not approved in the US or EU, and no fetched source records an approval anywhere else either. A search of the FDA label database returns no matches, and DailyMed returns zero documents for the drug name. Filed is not the same as approved, and CagriSema is now firmly in that gap: Novo Nordisk announced on 18 December 2025 that it had submitted a New Drug Application to the FDA for once-weekly CagriSema, resting on results from REDEFINE 1 and REDEFINE 2. The sponsor has since said an FDA decision is anticipated by late 2026.
The regulatory picture is coherent: a drug with strong phase 3 data, filed in the United States but not approved there or in the European Union. That distinction matters more than it sounds. A filing is a company asking; an approval is a regulator answering. Until the answer comes, nothing about the legal availability of the drug has changed.
AdvancedWhy a filing rests on more than one trial
Regulators evaluate a drug on its full evidence package, not one trial. The sponsor states that the CagriSema weight-management submission rests on the two pivotal trials, REDEFINE 1 (3,417 adults with obesity or overweight and a complication, without diabetes) and REDEFINE 2 (1,206 adults with type 2 diabetes and obesity or overweight), with supporting safety and pharmacology from the wider program. Assembling, cleaning, and analyzing that combined dataset is why a submission can follow a topline announcement by many months.